Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• PARP inhibitors are effective in cancers with homologous recombination defects, such as those with BRCA1/BRCA2 mutations.
• Clinical trials demonstrate PARP inhibitors' efficacy and tolerability in treating BRCA-associated cancers.
• Tumor resistance and varied patient responses limit the long-term effectiveness of PARP inhibitors.

Purpose of the Study:

• To explore the mechanisms of resistance to PARP inhibitors beyond genetic reversion.
• To investigate potential strategies for patient stratification and overcoming treatment resistance.
• To highlight the role of preclinical models in advancing PARP inhibitor therapy.

Main Methods:

• Review of existing clinical trial data (Phase I and II).
• Analysis of fundamental and preclinical research on PARP inhibitor resistance.
• Identification of genetic and non-genetic resistance mechanisms.

Main Results:

• Genetic reversion of BRCA mutations is the only identified resistance mechanism in human tumors to date.
• Preclinical data suggest additional resistance mechanisms including BRCA1 hypomorphic activity, drug efflux pumps, and DNA damage response alterations.
• Varied patient responses and eventual tumor resistance are significant clinical challenges.

Conclusions:

• While PARP inhibitors are effective, resistance necessitates further investigation into diverse resistance mechanisms.
• Preclinical models are crucial for developing strategies to stratify patients and counteract resistance.
• Understanding and addressing resistance pathways will improve therapeutic outcomes for patients with BRCA-mutated cancers.